Bolt Biotherapeutics, Inc. (BOLT): Price and Financial Metrics
GET POWR RATINGS... FREE!
BOLT POWR Grades
- Value is the dimension where BOLT ranks best; there it ranks ahead of 71.2% of US stocks.
- BOLT's strongest trending metric is Sentiment; it's been moving down over the last 177 days.
- BOLT's current lowest rank is in the Momentum metric (where it is better than 5.13% of US stocks).
BOLT Stock Summary
- BOLT BIOTHERAPEUTICS INC's stock had its IPO on February 5, 2021, making it an older stock than just 7.88% of US equities in our set.
- Of note is the ratio of BOLT BIOTHERAPEUTICS INC's sales and general administrative expense to its total operating expenses; merely 9.39% of US stocks have a lower such ratio.
- As for revenue growth, note that BOLT's revenue has grown 541.75% over the past 12 months; that beats the revenue growth of 97.98% of US companies in our set.
- Stocks that are quantitatively similar to BOLT, based on their financial statements, market capitalization, and price volatility, are TNGX, ALPN, GRTS, BPMC, and LPTX.
- Visit BOLT's SEC page to see the company's official filings. To visit the company's web site, go to www.boltbio.com.
BOLT Valuation Summary
- BOLT's price/earnings ratio is -0.6; this is 102.64% lower than that of the median Healthcare stock.
- Over the past 24 months, BOLT's price/earnings ratio has gone up 17.1.
Below are key valuation metrics over time for BOLT.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| BOLT | 2023-01-20 | 11.2 | 0.3 | -0.6 | -0.7 |
| BOLT | 2023-01-19 | 10.8 | 0.3 | -0.5 | -0.7 |
| BOLT | 2023-01-18 | 11.2 | 0.3 | -0.6 | -0.7 |
| BOLT | 2023-01-17 | 11.9 | 0.3 | -0.6 | -0.7 |
| BOLT | 2023-01-13 | 11.7 | 0.3 | -0.6 | -0.7 |
| BOLT | 2023-01-12 | 11.5 | 0.3 | -0.6 | -0.7 |
BOLT Price Target
For more insight on analysts targets of BOLT, see our BOLT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $39.75 | Average Broker Recommendation | 1.2 (Strong Buy) |
BOLT Stock Price Chart Interactive Chart >
BOLT Price/Volume Stats
| Current price | $1.47 | 52-week high | $3.99 |
| Prev. close | $1.46 | 52-week low | $1.18 |
| Day low | $1.42 | Volume | 126,100 |
| Day high | $1.47 | Avg. volume | 225,056 |
| 50-day MA | $1.38 | Dividend yield | N/A |
| 200-day MA | $1.73 | Market Cap | 55.36M |
Bolt Biotherapeutics, Inc. (BOLT) Company Bio
Bolt Biotherapeutics, Inc. operates as a biotechnology company. The Company develops immune-stimulating antibody conjugates, a new class of cancer therapeutics, which systemically-administered and uncover the immune system to induce anti-tumor immunity. Bolt Biotherapeutics serves healthcare industry in the United States.
Latest BOLT News From Around the Web
Below are the latest news stories about BOLT BIOTHERAPEUTICS INC that investors may wish to consider to help them evaluate BOLT as an investment opportunity.
Here's Why We're Watching Bolt Biotherapeutics' (NASDAQ:BOLT) Cash Burn SituationEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |
Bolt Biotherapeutics Appoints Laura Berner to Board of DirectorsREDWOOD CITY, Calif., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced the appointment of Laura Berner to its Board of Directors effective Dec. 14, 2022. “Laura is an accomplished biopharmaceutical executive with impressive corporate leadership, operations, and business development experience,” said Randall Schatzman, Ph.D., Chief Executive Officer |
Bolt Biotherapeutics (BOLT) Gets a Buy from JonesTradingIn a report released today, Soumit Roy from JonesTrading maintained a Buy rating on Bolt Biotherapeutics (BOLT - Research Report), with a price target of $4.00. The company's shares closed yesterday at $1.29.Roy covers the Healthcare sector, focusing on stocks such as Curis, Aeglea Biotherapeutics, and Day One Biopharmaceuticals. According to TipRanks, Roy has an average return of 9.4% and a 34.50% success rate on recommended stocks. Bolt Biotherapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $6.00, a 365.12% upside from current levels. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $8.00 price target. |
Bolt Biotherapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update– BDC-1001 dose-escalation clinical trial on track to complete recruitment by year-end 2022– BDC-3042 on track to enter the clinic in 2023; new preclinical data presented at SITC 2022– Cash balance of $209.6 million anticipated to fund key milestones through 2025 REDWOOD CITY, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results |
Bolt Biotherapeutics to Present Preclinical Data on BDC-3042, Dectin-2 Targeting Agonistic Antibody, at the SITC Annual MeetingREDWOOD CITY, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that it will be presenting a poster with new preclinical data on BDC-3042, a Dectin-2 targeting agonistic antibody, at the 2022 Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting. The conference is being held both virtually and at the Boston Convention and Exhibition |
BOLT Price Returns
| 1-mo | 11.36% |
| 3-mo | 5.00% |
| 6-mo | -32.26% |
| 1-year | -57.27% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 13.08% |
| 2022 | -73.47% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...